This guideline addresses the documentation on the chemical and pharmaceutical quality of IMPs and Auxiliary Medicinal Products containing chemically defined drug substances, synthetic peptides, synthetic oligonucleotides, herbal substances, herbal preparations and chemically defined radio- active/radio-labelled substances to be submitted to the competent authority for approval prior to beginning a clinical trial in humans.


Posted on the EMA website on 12 April 2016